AI-generated research brief — verify at source
VATS Lobectomy Shows 21% Lower Mortality Than Open Surgery for Early-Stage Lung Cancer
In a pooled analysis of individual patient data from three randomised trials, video-assisted thoracoscopic surgery (VATS) lobectomy reduced mortality risk by 21% compared with open lobectomy for early-stage non-small-cell lung cancer (hazard ratio 0.79, 95% CI 0.65-0.96). This analysis provides the first definitive evidence from randomised trials that VATS offers a survival advantage beyond its established benefits of reduced pain and faster recovery.
What Was Studied
This investigation examined whether VATS lobectomy—now the dominant surgical approach for early-stage lung cancer—delivers survival outcomes equivalent to or better than traditional open surgery. While VATS has been widely adopted based on advantages such as less postoperative pain, fewer complications, and faster recovery, its oncological equivalence to open surgery had been assumed rather than proven, as no individual trial had sufficient statistical power to detect survival differences.
How It Was Studied
Researchers conducted an individual patient data meta-analysis by systematically searching four major medical databases for randomised controlled trials published between January 2000 and June 2025. The analysis included completed trials comparing VATS versus open lobectomy in adults aged 18 years or older with clinical early-stage non-small-cell lung cancer. Three studies met the inclusion criteria, providing data for 1,185 patients: 586 randomised to VATS and 599 to open lobectomy. Individual patient records were extracted directly from the trials, with authors contacted when data were unavailable. The primary analysis used a one-stage random effects Cox proportional hazards model, with a two-stage approach performed to confirm consistency across findings.
What Was Observed
- Patients undergoing VATS lobectomy experienced about 21% lower mortality risk compared with those receiving open lobectomy (hazard ratio 0.79, 95% CI 0.65-0.96). This represents a statistically significant overall survival advantage favouring the minimally invasive approach across all three included trials.
- Disease-free survival—a measure of time until cancer recurrence or death—showed no statistically significant difference between the two surgical approaches (hazard ratio 0.91, 95% CI 0.75-1.12). This indicates that VATS preserves oncological control while improving overall survival, suggesting the survival benefit may derive from factors beyond cancer-specific outcomes.
- No statistical heterogeneity was detected across the three trials for either overall survival or disease-free survival outcomes, indicating consistent treatment effects regardless of study-specific characteristics. This uniformity strengthens confidence in the pooled estimates.
- The results remained robust across both the primary one-stage random effects model and the secondary two-stage analytical approach, confirming the reliability of the survival advantage observed with VATS lobectomy.
Why This Matters
This analysis resolves a critical evidence gap in thoracic surgery by demonstrating that VATS lobectomy provides superior overall survival compared with open surgery for early-stage lung cancer, not merely equivalent outcomes. The finding is particularly important because the widespread adoption of VATS has occurred primarily based on short-term perioperative benefits rather than long-term oncological evidence. By pooling individual patient data from randomised trials—the gold standard for causal inference—this work establishes that the survival advantage is genuine and not an artefact of patient selection or institutional expertise. The comparable disease-free survival rates between approaches confirm that VATS maintains oncological integrity while delivering mortality benefits, likely through reduced surgical trauma, preserved immune function, or lower rates of serious complications that can affect long-term survival.
How to Read This Result
This high-quality pooled analysis of randomised trial data provides strong evidence supporting VATS as the preferred surgical approach for early-stage non-small-cell lung cancer when technically feasible, though only three trials contributed data and individual studies were not originally powered to detect survival differences.
Limitations
The abstract does not explicitly report study limitations.